Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by CytoDyn Inc.

CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
December 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
September 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Settlement with Amarex Clinical Research LLC
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn to Host Webcast to Provide Company Update
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
May 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces FDA Has Lifted Clinical Hold
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Webcast to Provide Company Update
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
November 2023 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Company Updates and Investment Community Update Webcast
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces President Takes Medical Leave of Absence
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn to Hold Webcast to Provide a Company Update
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Appointment of Additional Directors with Industry Experience
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.